More frequent lab tests will be recommended for patients taking Arava (leflunomide)

January 2004

More frequent lab tests will be recommended for patients taking Arava (leflunomide).

This is due to potential hepatotoxicity or severe infections due to immunosuppression.

The biggest concern is for patients with other risk factors for hepatotoxicity or immunosuppression.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote